ASCO 2020：11项中国研究工作入选口头报告，17项Poster报告

深受全球新近冠疫情影响，原定于5年末29日~6年末2日在费城移师的宾夕法尼亚州医学研究成果会（ASCO）学术会议本年将首次以线上形式举办，这是目前最大规模的线上盛会。以前，大会的内容可题目出炉，共103个sessions，华北地区共计11项研究成果入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他滨用于HER2+高血压乳腺癌（PHOEBE）：一项III期随机试制。

大舞台：高血压乳腺癌

编者：华北地区医学科学院该医院徐兵河名誉教授、马飞名誉教授，华东师范大学附属该医院胡夕春名誉教授等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可动手术三阴适度乳腺癌标准外科动手术后卡培他滨维系旋律治疗的III期试制（SYSUCC-001）。

大舞台：乳腺癌—渐进/地区/来进行外科动手术

编者：当岭南大学防控当该中心三王树森名誉教授等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

并用高血压脑的表型形态来预测脑组织当中循环DNA检测的几率: 新近工具对抗据说对手

大舞台：新近工具解决据说问题

编者：李美芹 李德兰等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

伊克非尼对卢比拉非尼作为更早肺巨噬细胞腺癌的一线外科动手术：一项新近开标记、随机、多当该中心II/III期试制。

大舞台：消化系统腺癌—小肠静脉、坏死和肺胆

编者：武汉大学特罗斯季亚涅齐该医院毕锋名誉教授、华北地区人民解放军双十该医院秦叔逵名誉教授等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

华北地区更早肺腺癌高血压阿帕替尼二线外科动手术：一项随机、口服对应、双盲III期研究成果

大舞台：消化系统腺癌—小肠静脉、坏死和肺胆

编者：华北地区人民解放军双十该医院秦叔逵名誉教授、武汉大学特罗斯季亚涅齐该医院李秋名誉教授等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

更早病情恶化适度乳腺癌二次巨噬细胞减灭术的一项随机III期试制：SOC1 / SGOG-OV2。

栏目：儿科前列腺癌

编者：华东师范大学附属当大同该医院臧荣余名誉教授等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈腺癌根治适度子宫外科手术后来进行外科动手术当中的序贯放治疗对比单独放疗或该系统放治疗（STARS研究成果）：一项随机、对应、新近开标记的III期试制。

大会：儿科前列腺癌

编者：当岭南大学防控当该中心大白名誉教授、刘继红名誉教授等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：来进行吉非替尼对比治疗用于可切除的EGFR基因型的N1-N2期NSCLC-随机III期医学试制的终究整体而言生存统计分析。

栏目：膀胱腺癌—非小巨噬细胞渐进-地区/小巨噬细胞/其他背部

编者：江门市人民该医院吴一龙名誉教授等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因型寡转回非小巨噬细胞膀胱腺癌高血压一线色氨酸激酶抑制剂牵头或不牵头更进一步支部队渐进放疗：III期新近开标记医学随机试制（SINDAS）的当初期结果（NCT02893332）。

栏目：膀胱腺癌-非小巨噬细胞转回

编者：绵阳市人民该医院曾铭名誉教授等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序适度死亡-1（PD-1）的人源化IgG4单克隆抗体牵头阿昔替尼用于高血压上皮细胞黑色素腺高血压的Ib期研究成果的总生存期和有机体标志物统计分析。

栏目：黑色素腺/皮肤腺癌

编者：南京大学该医院郭军、盛锡楠名誉教授等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的有效适度和结果：通用CAR-T巨噬细胞首次有机体体试制外科动手术病情恶化/难治适度T巨噬细胞急适度上皮巨噬细胞前列腺癌（r/r T-ALL）的有效适度和。大会：开发当中的外科动手术技术-免疫外科动手术。编者：三斌欣等内容可：3013标语：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利霉素在更早静脉表皮巨噬细胞腺癌高血压当中的领域：一项随机的新近开标记II期试制（ORIENT-2）。大会：消化系统腺癌-小肠静脉腺癌、肺腺癌和肺胆道腺癌编者：徐建明名誉教授等内容可：4511标语：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异适度CAR-T巨噬细胞对髓母巨噬细胞腺的根除适度外科动手术大会：当神经编者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东内容可：2522标语。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在更早错配修复弱点高血压当中的领域大会：开发当中的外科动手术学-免疫外科动手术编者：沈琳名誉教授等内容可：3021标语。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 增生CD7-CART外科动手术病情恶化/难治适度ACUTE上皮巨噬细胞前列腺癌/淋巴腺的首例有机体体医学试制大会: 开发适度外科动手术学-免疫外科动手术编者简介：张明志，杨林等内容可：3026标语: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）牵头领域于更早实体腺高血压的Ib期研究成果大会：发展适度外科动手术学--分子结构抑制剂药物和有机体学编者：龚继芳，沈琳名誉教授等内容可：3523标语：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin牵头萘和nedaplatin外科动手术病情恶化适度或高血压静脉表皮巨噬细胞腺癌（ESCC）高血压的II期研究成果。大会：消化系统腺癌-小肠静脉、坏死和肺胆道腺癌的研究成果编者：三王志强，李玉红，三王德申，三王凤华，任超，谭琼 三王志强、李玉红、三王德深、三王凤华、任超、谭琼内容可：4522标语：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.大会：消化系统腺癌-小肠静脉腺癌、肺腺癌和肺胆管腺癌的二线外科动手术编者：宋艳等内容可：4524标语：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体外侧RNA方差用于初始活检时检测高等级腺癌的尿液外体外侧RNA方差：一项多当该中心的回顾适度研究成果大会：循环系统生殖前列腺癌---腺癌、睾丸腺癌和腺癌编者简介：Liaoyuan Li等内容可：5522标语。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 渐进更早宫颈腺癌并发治疗后的来进行治疗大会: 儿科前列腺癌编者简介： 李珉珉等内容可：6031标语：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼外科动手术睾丸髓适度腺癌的不确定适度：基于ALTER01031试制的统计分析。会话里：鳞状编者：天津市该医院据说练名誉教授内容可：6526标语。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼外科动手术后高血压第一集的影响: ALTER01031的亚组统计分析大会：鳞状编者：天津市该医院据说练名誉教授内容可：6527标语。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA统计分析预测I-IIIA期非小巨噬细胞膀胱腺癌（NSCLC）高血压术后病情恶化: GASTO1035和GASTO1018的结果大会：膀胱腺癌-非小巨噬细胞渐进-地区适度/小巨噬细胞/小巨噬细胞/其他胸科前列腺癌编者：Si-Yu Wang等内容可：9023标语：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞膀胱腺癌（NSCLC）当中EGFR色氨酸激酶抑制剂的新近型耐药的系统大会:膀胱腺癌-非小巨噬细胞高血压膀胱腺癌编者简介：赵昕，金大姐，满宇，欧秋香，梅氏，薛武，杨少，范敏 赵昕、金大姐、满宇、欧秋香、梅氏、薛武、杨绍、范敏内容可：9528标语：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试制当中更早黑色素腺总生存的替代终点大会：黑色素腺/皮肤腺癌编者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟内容可：10030标语：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼外科动手术病情恶化或高血压原发适度恶适度骨高血压的II期研究成果大会： 肉腺编者：唐丽娜，牛晓辉，三王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、三朝臣、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525标语。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 近期评价安罗替尼在更早肉腺高血压多线外科动手术当中的有效适度和。大会：肉腺编者：姚伟涛，三王侯强，玑，三斌，杜新近辉，田志浩，牛晓颖 姚伟涛、三王侯强、玑、三王鑫、杜鑫辉、田志超、牛晓英内容可：11526标语：414